At a glance
- Originator Nihon Schering
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Peripheral nervous system diseases